Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
05
2021
accepted:
14
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
24
11
2021
Statut:
epublish
Résumé
The first symptoms of schizophrenia (SCHZ) are usually observed during adolescence, a developmental period during which first exposure to psychoactive drugs also occurs. These epidemiological findings point to adolescence as critical for nicotine addiction and SCHZ comorbidity, however it is not clear whether exposure to nicotine during this period has a detrimental impact on the development of SCHZ symptoms since there is a lack of studies that investigate the interactions between these conditions during this period of development. To elucidate the impact of a short course of nicotine exposure across the spectrum of SCHZ-like symptoms, we used a phencyclidine-induced adolescent mice model of SCHZ (2.5mg/Kg, s.c., daily, postnatal day (PN) 38-PN52; 10mg/Kg on PN53), combined with an established model of nicotine minipump infusions (24mg/Kg/day, PN37-44). Behavioral assessment began 4 days after the end of nicotine exposure (PN48) using the following tests: open field to assess the hyperlocomotion phenotype; novel object recognition, a declarative memory task; three-chamber sociability, to verify social interaction and prepulse inhibition, a measure of sensorimotor gating. Phencyclidine exposure evoked deficits in all analyzed behaviors. Nicotine history reduced the magnitude of phencyclidine-evoked hyperlocomotion and impeded the development of locomotor sensitization. It also mitigated the deficient sociability elicited by phencyclidine. In contrast, memory and sensorimotor gating deficits evoked by phencyclidine were neither improved nor worsened by nicotine history. In conclusion, our results show for the first time that nicotine history, restricted to a short period during adolescence, does not worsen SCHZ-like symptoms evoked by a phencyclidine-induced mice model.
Identifiants
pubmed: 34587208
doi: 10.1371/journal.pone.0257986
pii: PONE-D-21-15988
pmc: PMC8480744
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Phencyclidine
J1DOI7UV76
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257986Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurosci. 2007 Aug 1;27(31):8202-18
pubmed: 17670967
MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1276-1277
pubmed: 30439875
Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58
pubmed: 11549226
Curr Top Behav Neurosci. 2010;4:349-71
pubmed: 21312406
Am J Psychiatry. 2003 Feb;160(2):316-22
pubmed: 12562579
Addict Biol. 2021 Mar;26(2):e12891
pubmed: 32135573
Pharmacol Biochem Behav. 1998 Jun;60(2):473-88
pubmed: 9632231
Neurosci Biobehav Rev. 2005;29(6):1021-34
pubmed: 15964073
Neuropharmacology. 2016 Sep;108:49-59
pubmed: 27102349
Schizophr Res. 2013 Jun;147(1):125-131
pubmed: 23587696
Psychopharmacology (Berl). 2015 May;232(10):1681-92
pubmed: 25388292
Int Rev Neurobiol. 2007;78:1-39
pubmed: 17349856
Psychol Med. 2013 Aug;43(8):1651-60
pubmed: 23149169
Neurotox Res. 2007 Dec;12(4):233-46
pubmed: 18201951
Schizophr Bull. 2003;29(4):703-15
pubmed: 14989408
Eur J Pharmacol. 2015 May 5;754:190-8
pubmed: 25744879
Int J Neuropsychopharmacol. 2019 Jan 1;22(1):19-27
pubmed: 30239793
Eur Neuropsychopharmacol. 2020 Dec;41:92-105
pubmed: 33109433
Neuropsychopharmacology. 2015 Sep;40(10):2327-36
pubmed: 25790020
Neurosci Biobehav Rev. 2008 Jul;32(5):1014-23
pubmed: 18471877
Br J Pharmacol. 2011 Oct;164(4):1162-94
pubmed: 21449915
Behav Brain Res. 2011 Aug 1;221(1):282-9
pubmed: 21402108
Can J Psychiatry. 2019 Jan;64(1):5-17
pubmed: 29742910
Neuroscience. 2009 Sep 15;162(4):1174-86
pubmed: 19465085
Biol Psychiatry. 2017 Jan 1;81(1):52-66
pubmed: 27452791
Psychiatry J. 2019 Apr 16;2019:9804836
pubmed: 31139639
Neuropharmacology. 2020 Jun 15;170:108053
pubmed: 32188568
Nicotine Tob Res. 2008 Dec;10(12):1691-715
pubmed: 19023823
Behav Brain Res. 2001 Aug 1;122(2):159-67
pubmed: 11334646
Rev Neurosci. 1999;10(1):59-90
pubmed: 10356992
Behav Brain Res. 2007 Jul 19;181(1):136-46
pubmed: 17481743
Neuropsychopharmacology. 2004 Oct;29(10):1865-77
pubmed: 15127085
Toxicol Res. 2020 Jun 5;37(1):115-124
pubmed: 33489862
Psychiatry Res. 2011 Jul 30;188(2):208-16
pubmed: 21555157
Addict Biol. 2003 Dec;8(4):419-27
pubmed: 14690878
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18459-64
pubmed: 22032926
Psychiatry Res. 2011 Nov 30;190(1):79-84
pubmed: 21636135
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110310
pubmed: 33775743
Neuropsychiatr Dis Treat. 2019 Oct 16;15:2943-2958
pubmed: 31802874
Biochem Pharmacol. 2017 Nov 15;144:1-17
pubmed: 28599850
Front Psychiatry. 2019 May 13;10:298
pubmed: 31133894
Int J Dev Neurosci. 2020 May;80(3):197-207
pubmed: 32077124
Compr Psychiatry. 2018 Jan;80:155-162
pubmed: 29096206
Psychiatr Clin North Am. 2002 Dec;25(4):837-53
pubmed: 12462863
Lancet Psychiatry. 2018 Aug;5(8):664-677
pubmed: 29602739
Schizophr Res. 2009 May;110(1-3):1-23
pubmed: 19328655
Neural Plast. 2011;2011:723184
pubmed: 21904685
Neuropsychopharmacology. 1998 Jul;19(1):18-25
pubmed: 9608573
Schizophr Res. 2015 Apr;163(1-3):1-8
pubmed: 25795083
Nicotine Tob Res. 2004 Oct;6(5):853-62
pubmed: 15700921
Arch Gen Psychiatry. 2011 Dec;68(12):1195-206
pubmed: 21810630
Pharmacol Biochem Behav. 2020 Oct;197:173010
pubmed: 32738256
Neurosci Biobehav Rev. 2020 Sep;116:415-425
pubmed: 32679232
Pharmacol Biochem Behav. 1997 Dec;58(4):1131-8
pubmed: 9408224
Am J Psychiatry. 1991 Nov;148(11):1474-86
pubmed: 1681750
Prog Neurobiol. 2010 Oct;92(2):105-11
pubmed: 20558239
CNS Drugs. 2015;29(10):819-32
pubmed: 26482261
Neuropsychopharmacology. 2012 Feb;37(3):660-8
pubmed: 22048460
Curr Pharm Des. 2014;20(31):5104-14
pubmed: 24345269
Ann N Y Acad Sci. 2015 Sep;1349:46-63
pubmed: 26301866
J Chromatogr Sci. 2009 Feb;47(2):170-7
pubmed: 19222926
Expert Opin Drug Discov. 2018 Jul;13(7):671-683
pubmed: 29587555
Nicotine Tob Res. 2019 Feb 18;21(3):349-356
pubmed: 30137618
Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:17-30
pubmed: 25455585
Neuropsychiatr Dis Treat. 2015 Dec 17;11:3111-25
pubmed: 26719696
JAMA. 2014 Jan 8;311(2):172-82
pubmed: 24399556
Neurosci Biobehav Rev. 2016 Aug;67:41-56
pubmed: 26743857
Br J Pharmacol. 2014 Apr;171(7):1758-71
pubmed: 24417347
Toxicol Sci. 2011 Sep;123(1):144-54
pubmed: 21633116
Neuropharmacology. 2021 Feb 15;184:108411
pubmed: 33245960
CNS Spectr. 2018 Jun;23(3):187-191
pubmed: 29954475
Int J Neuropsychopharmacol. 2015 May;18(7):pyu114
pubmed: 26478928
J Res Adolesc. 2011 Mar 1;21(1):21-33
pubmed: 21475613
Arch Gen Psychiatry. 2004 Nov;61(11):1107-15
pubmed: 15520358
Curr Opin Psychiatry. 2010 Mar;23(2):91-6
pubmed: 20051858
Acta Psychiatr Scand. 2018 Jul;138(1):5-14
pubmed: 29457219
Drug Alcohol Depend. 2013 Nov 1;133(1):52-60
pubmed: 23810373
Transl Psychiatry. 2021 May 6;11(1):271
pubmed: 33958577
Neurosci Biobehav Rev. 2001 Jul;25(5):427-43
pubmed: 11566480
Neuropharmacology. 2018 Nov;142:41-62
pubmed: 29196183
Schizophr Res. 2018 Feb;192:269-273
pubmed: 28412088
Trends Neurosci. 2014 Apr;37(4):200-10
pubmed: 24656971
MMWR Morb Mortal Wkly Rep. 2016 Apr 15;65(14):361-7
pubmed: 27077789
Pharmacol Ther. 2009 Jun;122(3):302-11
pubmed: 19351547
Eur J Neurosci. 2000 Mar;12(3):973-9
pubmed: 10762327
Neuropsychopharmacology. 2008 Feb;33(3):599-610
pubmed: 17460612
Nature. 2014 May 15;509(7500):282-3
pubmed: 24834516
Schizophr Res. 2020 Jan;215:38-48
pubmed: 31784336
MMWR Morb Mortal Wkly Rep. 2019 Oct 04;68(39):839-844
pubmed: 31581163
Trends Neurosci. 1997 Feb;20(2):92-8
pubmed: 9023878
J Neurosci. 2010 Oct 13;30(41):13814-25
pubmed: 20943922
Schizophr Res. 2005 Jul 15;76(2-3):135-57
pubmed: 15949648
Int J Neuropsychopharmacol. 2009 Mar;12(2):243-55
pubmed: 18684341
Int Rev Neurobiol. 2015;124:23-78
pubmed: 26472525
Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33
pubmed: 12600700
Front Psychiatry. 2013 May 20;4:38
pubmed: 23730292
Schizophr Bull. 2007 Jul;33(4):971-81
pubmed: 17519393
Front Neuroendocrinol. 2017 Oct;47:19-33
pubmed: 28673758
Psychopharmacology (Berl). 2002 Jan;159(3):248-57
pubmed: 11862357
Behav Genet. 2004 May;34(3):343-54
pubmed: 14990873
Schizophr Bull. 2010 Jan;36(1):173-81
pubmed: 18562340
Neuropsychopharmacology. 2003 Nov;28(11):1935-49
pubmed: 12784097
Rev Neurosci. 2013;24(4):389-400
pubmed: 23843581
Front Behav Neurosci. 2015 Feb 11;9:30
pubmed: 25717295
Br J Psychiatry. 2005 Mar;186:215-21
pubmed: 15738502
Am J Prev Med. 2016 Dec;51(6):958-966
pubmed: 27522471
Neuropharmacology. 2012 Mar;62(3):1371-80
pubmed: 21420988
N Engl J Med. 2019 Jan 10;380(2):192-193
pubmed: 30554549
Ther Adv Psychopharmacol. 2015 Feb;5(1):43-58
pubmed: 25653831
Neurobiol Learn Mem. 2013 Oct;105:63-80
pubmed: 23827407
Curr Psychiatry Rep. 2010 Aug;12(4):327-34
pubmed: 20544314
J Psychopharmacol. 2018 Dec 3;33(1):269881118812097
pubmed: 30501536